title: Beneficial effects of timolol on infarct size and late ventricular tachycardia in patients with acute myocardial infarction.
abstract: This investigation was undertaken to study the effects of beta-adrenergic blockade with timolol on infarct size and on the incidence of late ventricular tachycardia in patients with acute myocardial infarction of less than 6 hr of evolution. Patients were assigned randomly either to a placebo-treated group (98 patients) or to a timolol-treated group (102 patients). The patients were treated with 5.5 mg iv timolol (or matched placebo) as a bolus divided into four doses during the first 2 hr followed by 10 mg orally twice daily for 1 month. Cumulative total creatine kinase (CK) release, which reflects the amount of myocardial necrosis was 1677 +/- 132 IU/liter in the placebo group (n = 83) and 1274 +/- 73 IU/liter in the timolol group (n = 81, p less than .01), a 24% reduction. Cumulative release of CK-MB was 138 +/- 8 IU/liter in the placebo group and 106 +/- 8 IU/liter in the timolol group (p less than .01), a 23% reduction. Twenty-four hour Holter electrocardiograms were obtained on days 7, 14, 21, and 28 after the onset of the acute myocardial infarction in 80 patients in the placebo group and 82 patients in the timolol group. The incidence of ventricular tachycardia was lower in the timolol than in the placebo group (7 vs 16 patients, p = .05). We conclude that early administration of intravenous timolol followed by oral treatment in patients with acute myocardial infarction reduces infarct size as assessed by CK and CK-MB serum activity, and decreases the occurrence of late ventricular tachycardia.
authors.forename: F
authors.initials: F
authors.lastname: Roqué
authors.forename: L M
authors.initials: LM
authors.lastname: Amuchastegui
authors.forename: M A
authors.initials: MA
authors.lastname: Lopez Morillos
authors.forename: G A
authors.initials: GA
authors.lastname: Mon
authors.forename: A L
authors.initials: AL
authors.lastname: Girotti
authors.forename: S
authors.initials: S
authors.lastname: Drajer
authors.forename: M
authors.initials: M
authors.lastname: Fortunato
authors.forename: E
authors.initials: E
authors.lastname: Moreyra
authors.forename: P
authors.initials: P
authors.lastname: Tuero
authors.forename: J C
authors.initials: JC
authors.lastname: Solchaga
mesh_terms: D001794:Blood Pressure; D002637:Chest Pain / Q000175:diagnosis; D004796:Clinical Enzyme Tests; D002986:Clinical Trials as Topic; D003402:Creatine Kinase / Q000097:blood; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate; D006352:Heart Ventricles; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy*; D011897:Random Allocation; D013610:Tachycardia / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D013999:Timolol / Q000627:therapeutic use*
chemical_list: D007527:Isoenzymes; D013999:Timolol; D003402:Creatine Kinase